发给老马备查:' Y6 s/ t V! z( z4 N
滴水察海(69304838) 15:23:23# ]. v0 @7 _% G$ _' e% U1 K5 X
老马,我看到培美和S-1都提到TS低表达,而鳞多半不是低表达,是不是S-1不靠谱, f( g/ } V, U1 U; O
吉非替尼和S-1连用的依据1 ^, m' x2 C& k* C3 p8 D( f( \
Gefitinib induced down-regulation of thymidylate synthase and E2F-1 in gefitinib-resistant NSCLC cells with MET amplification but not in those harboring the T790M mutation of EGFR. The combination of 5-fluorouracil and gefitinib synergistically inhibited the proliferation of cells with MET amplification, but not that of those with the T790M mutation of EGFR, in vitro.: F) [( v5 ~+ F( t% @$ g
是不是说因C-MET引起的耐药中,吉非替尼会引导TS低表达7 L- `) C' S Q* u
这样是不是推理出,耐药后,可以用S-1和培美了?+ @/ X, n% v$ U- C1 g8 V
结论:
7 \5 f; O0 j, U) j# J如果是T790M突变引起的耐药,则2992有效,如果是C-MET扩增引起的突变,则除了184,还可以特+S1联用,而且可能可以用培美。 |